Eledon Pharmaceuticals, Inc. (ELDN)

NASDAQ: ELDN · IEX Real-Time Price · USD
2.40
-0.03 (-1.23%)
Jun 29, 2022 11:57 AM EDT - Market open
-1.23%
Market Cap 33.02M
Revenue (ttm) n/a
Net Income (ttm) -35.87M
Shares Out 13.76M
EPS (ttm) -2.44
PE Ratio n/a
Forward PE 4.64
Dividend n/a
Ex-Dividend Date n/a
Volume 957
Open 2.45
Previous Close 2.43
Day's Range 2.40 - 2.45
52-Week Range 2.27 - 8.49
Beta 1.93
Analysts Buy
Price Target 25.91 (+979.6%)
Earnings Date Aug 11, 2022

About ELDN

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the trea... [Read more...]

Industry Biotechnology
Founded 2004
CEO Gregory Flesher
Employees 12
Stock Exchange NASDAQ
Ticker Symbol ELDN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ELDN stock is "Buy." The 12-month stock price forecast is 25.91, which is an increase of 979.58% from the latest price.

Price Target
$25.91
(979.58% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IRVINE, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innov...

Penny Stocks To Buy Now? 3 To Watch This Week

Penny stocks to watch this week. The post Penny Stocks To Buy Now?

Other symbols: GFAIGRABMULN

Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement,...

IRVINE, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innova...

Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results

Topline data for Phase 2a tegoprubart study in amyotrophic lateral sclerosis (ALS) anticipated in June 2022

Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

Management to host conference call and webcast at 4:30 p.m. ET Management to host conference call and webcast at 4:30 p.m. ET

Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference

IRVINE, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of inno...

Eledon to Host Virtual R&D Day on Thursday, April 28, 2022

IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of inno...

Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results

Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022

Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022

Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET

Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference

IRVINE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innov...

Eledon Pharmaceuticals to Participate in January 2022 Investor Conferences

IRVINE, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innov...

Eledon Pharmaceuticals Reports Third Quarter 2021 Operating and Financial Results

Nearing full enrollment in ALS Phase 2 Study; topline data expected 1H 2022

Eledon Pharmaceuticals CEO David-Alexandre C. Gros, M.D.

Presentation to focus on potential use of AT-1501 in kidney transplantation as well as research collaboration between Eledon and CareDx to help assess the efficacy of Eledon's investigational AT-1501 fo...

Eledon Pharmaceuticals Announces Participation in November Conferences

IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons ...

Eledon Pharmaceuticals to Release Third Quarter Financial Results on Thursday, November 11, 2021

Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET

Eledon Pharmaceuticals Announces Presentation on AT-1501 at the Virtual 2021 Northeast Amyotrophic Lateral Sclerosis ...

IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons ...

Eledon Pharmaceuticals Announces Upcoming Presentation on AT-1501 at the Virtual 2021 International Pancreas and Isle...

IRVINE, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons ...

Eledon Pharmaceuticals to Present at Two Investor Conferences in September

IRVINE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons...

A Duo of Net Current Asset Value Stock Picks to Consider

There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can get a huge return out of these stocks after the market has reasses...

Other symbols: RWLK

Eledon Pharmaceuticals Reports Second Quarter 2021 Operating and Financial Results

Received approval from Health Canada to initiate a clinical trial of AT-1501 in kidney transplantation; company expects to initiate trial in Q4 with initial data in late 2022

Eledon Pharmaceuticals to Release Second Quarter Financial Results on Thursday, August 12, 2021

Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET

Eledon Pharmaceuticals Receives Health Canada Approval to Commence Human Trials to Evaluate AT-1501 in Kidney Transpl...

Interim data expected in late 2022 in a multicenter, open label study to replace tacrolimus with AT-1501

Eledon Pharmaceuticals Appoints Jan Hillson, M.D., to its Board of Directors

IRVINE, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons ...

Eledon Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference

IRVINE, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons ...

Eledon Pharmaceuticals to Present at the 2021 Jefferies Virtual Healthcare Conference

IRVINE, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons l...